Standard enteral formulas will lead enteral nutrition sales through 2036 with 50.0% of the product segment in 2026. Gastrointestinal disorders lead applications with a 40.0% share. The market was valued at USD 8.69 billion in 2025 and is expected to be worth USD 16.67 billion by 2036, creating an incremental opportunity of USD 7.45 billion.